Non-specific Endonucleases Market Size, Share, Trends, Industry Analysis Report
By Product (Recombinant Non-Specific Endonucleases, Natural Source Enzymes, Engineered/Modified Variants), By Application, By End User, and By Region – Market Forecast, 2025–2034
- Published Date:Nov-2025
- Pages: 122
- Format: PDF
- Report ID: PM6519
- Base Year: 2024
- Historical Data: 2020-2023
Overview
The global non-specific endonucleases market size was valued at USD 353.60 million in 2024, growing at a CAGR of 6.15% from 2025 to 2034. Global growth in healthcare and biotech R&D spending along with the rising prevalence of genetic disorders is driving market growth.
Key Insights
- Recombinant non-specific endonucleases segment dominated the market in 2024.
- The natural source enzymes segment is projected to grow fastest due to rising use in cost-sensitive and academic research.
- North America held the largest share of the non-specific endonucleases market in 2024.
- The U.S. market driven by strong biotech infrastructure and extensive genomic research activities.
- Asia Pacific market to grow 2025–2034 from rising genomics and biopharma research investments.
- China and India lead expansion through government funding and growing biotechnology capabilities.
Industry Dynamics
- Rising global healthcare and biotech R&D is driving demand for non-specific endonucleases.
- Increasing prevalence of genetic disorders boosts use in diagnostics and therapeutic research applications.
- Advances in sequencing, automation, and enzyme engineering create new market opportunities.
- High enzyme costs and strict regulations limit adoption in small labs and emerging markets.
Market Statistics
- 2024 Market Size: USD 353.60 Million
- 2034 Projected Market Size: USD 641.80 Million
- CAGR (2025–2034): 6.15%
- North America: Largest Market Share
The non-specific endonucleases market targets enzymes employed in molecular biology, genomics, and research diagnostics. The enzymes allow research institutions and biotech firms to manipulate nucleic acids for use in gene editing, sequencing, and drug development. Supply outsourcing of the enzymes provides organizations with access to niche products without having to undertake in-house manufacturing.
Increasing healthcare and biotechnology R&D expenditures and rising incidences of genetic diseases are propelling the market. The global expansion of research in genomics, personalized medicine, and molecular diagnostics is driving the need for accurate and reliable enzymes. In April 2025, Worthington Biochemical released new non-specific endonucleases, NUCxyme DNA/RNA Nuclease and Ribonuclease U2, to improve DNA and RNA removal in bioprocessing.
Advancements in sequencing technology, lab automation platforms, and enzyme engineering are opening new opportunities for growth. Nonetheless, prohibitive enzyme prices and stringent regulatory conditions restrict usage in small labs and research institutions in emerging markets.
Drivers & Opportunities
Global increase in healthcare and biotech R&D spending: Rising global investment in healthcare and biotech research is expanding molecular biology studies. Companies are increasing budgets for genomics and enzyme-based projects. Thus, non-specific endonucleases are commonly adopted by labs and commercial processes. Also, rise in funding provides development for advanced enzyme technologies and automated platforms.
Rising prevalence of genetic disorders driving research needs: Increasing cases of genetic disorders are pushing demand for therapeutic and diagnostic research. About 25 to 30 million individuals in the U.S. are affected by rare genetic disorders each year, states the U.S. National Organization for Rare Disorders. Researchers require non-specific endonucleases for genome analysis, gene editing, and biomarker discovery. This is promoting adoption of enzyme solutions across global laboratories. With rising emphasis on precision medicine and targeted treatments further enhances market expansion.
Segmental Insights
Product Analysis
By product, the market is divided into recombinant non-specific endonucleases, natural source enzymes, and engineered/modified variants. The market led by the recombinant non-specific endonucleases segment in 2024 owing to strong demand within the research space of genomics and molecular biology.
Natural source enzymes segment is expected to register the highest CAGR led by growing adoption in cost-sensitive laboratories and research in academic circles. Moreover, the expanding interest for naturally sourced biocatalysts towards conducting sustainable research fuels the market growth.
Application Analysis
Based on source, the market is segmented into biopharmaceutical production, cell & gene therapy, vaccine manufacturing, diagnostics & research, and others applications. Biopharmaceutical production segment led the market in 2024, backed by growing enzyme application in process development and genome editing. Additionally, biologics pipeline expansion worldwide enhances demand for non-specific endonucleases in production processes.
The cell & gene therapy segment is expected to register the fastest CAGR, with growth attributed to growing investment in gene therapy research. In addition, growing adoption of enzymatic tools for precise genome manipulation accelerates market growth.
End User Analysis
Based on end user, the market is segmented into biopharmaceutical & biotechnology companies, contract development and manufacturing organizations (CDMOs/CMOs), academic & research institutions, and diagnostic laboratories. Biopharmaceutical and biotechnology companies led the market in 2024, led by significant R&D and enzyme application in production and analysis of genomes. These firms have advantages from outsourcing enzyme sourcing to concentrate on key drug development processes.
CDMOs/CMOs are expected to expand at the highest CAGR, led by outsourcing behavior in genomics and biopharma development. Furthermore, rising collaborations with research institutes enhance demand for non-specific endonucleases in contract-based usage.
Regional Analysis
North America dominated the market for non-specific endonucleases in 2024, driven by widespread healthcare and biotech R&D expenditures, fueling the use of enzymes in molecular biology research. Pharmaceuticals gained a record R&D investment of USD 102 million in 2024, a decade-high and steep jump from USD 71 million in 2023, with the U.S. accommodating approximately 55% of global R&D headquarters reported by Johnson & Johnson.
The U.S. Non-specific Endonucleases Market Insights
The U.S. dominates the North America market owing to high investment in genomics and precision medicine research. Moreover, robust regulatory environments and well-established biotech infrastructures foster the use of non-specific endonucleases. Additionally, increasing collaboration between commercial and academic laboratories drive the demand for the market.
Europe Non-specific Endonucleases Market Assessments
Europe is expected to hold a significant share of the market by 2034 driven by high prevalence of genetic disorder research and strong biotech infrastructure in countries like Germany and the UK. Moreover, government initiatives for personalized medicine support enzyme adoption. In addition, growing collaborations between universities and biotech firms enhance market growth.
Asia Pacific Non-specific Endonucleases Market Trends
Asia Pacific is expected to demonstrate the highest growth rate owing to rising biotechnology R&D and government funding in genomics research. In September 2025, global CFO of Illumina stated that demand for genomic sequencing in India is expected to grow four to five times in the next five years due to its rising use in clinical diagnosis, medical research, and drug development. Moreover, increasing adoption of molecular diagnostics in emerging economies supports enzyme growth in this region.
China Non-specific Endonucleases Market Overview
China dominated the Asia Pacific market, driven by huge government spending on life sciences and genome research. Furthermore, increasing biotechnology manufacturing capacities boost the use of enzymes. Additionally, rising genetic disorder awareness and precision medicine drive demand for non-specific endonucleases.
Key Players & Competitive Analysis
The market for non-specific endonucleases is moderately competitive as firms increase enzyme manufacturing and supply capacity, offering quality reagents to the biotechnology, pharmaceutical, and research academic organizations. Furthermore, partnerships with international research institutes and biotech companies sustain market adoption and regional expansion.
Some of the key players in the market for non-specific endonucleases are ArcticZymes Technologies, New England Biolabs (NEB), Thermo Fisher Scientific Inc., GenScript Biotech, Promega Corporation, QIAGEN N.V., TransGen Biotech, RayBiotech, Inc., ACROBiosystems, Protean Ltd., c-LEcta GmbH, and Kerafast.
Key Players
- ACROBiosystems
- ArcticZymes Technologies
- c-LEcta GmbH
- GenScript Biotech
- Kerafast
- New England Biolabs (NEB)
- Promega Corporation
- Protean Ltd.
- QIAGEN N.V.
- RayBiotech, Inc.
- Thermo Fisher Scientific Inc.
- TransGen Biotech
Non-specific Endonucleases Industry Developments
June 2025: ArcticZymes Technologies launched a GMP-grade non-specific endonuclease to improve DNA removal and manufacturing efficiency in viral vector and biologics production.
March 2025: c-LEcta launched a GMP-grade non-specific endonuclease, DENARASE High Salt, optimized for biologics and viral vector manufacturing under high-salt conditions.
Non-specific Endonucleases Market Segmentation
By Product Outlook (Revenue, USD Million, 2020–2034)
- Recombinant Non-Specific Endonucleases
- Natural Source Enzymes
- Engineered/Modified Variants
By Application Outlook (Revenue, USD Million, 2020–2034)
- Biopharmaceutical Production
- Monoclonal Antibodies (mAbs)
- Recombinant Proteins
- Biosimilars
- Cell & Gene Therapy
- AAV, Lentivirus, Oncolytic Viruses
- CAR-T and TCR Therapies
- Vaccine Manufacturing
- mRNA Vaccines
- Viral Vector Vaccines
- Diagnostics & Research
- Molecular Biology
- RNA Analysis & Sequencing Workflows
- Others Applications
By End User Outlook (Revenue, USD Million, 2020–2034)
- Biopharmaceutical & Biotechnology Companies
- Contract Development and Manufacturing Organizations (CDMOs/CMOs)
- Academic & Research Institutions
- Diagnostic Laboratories
By Regional Outlook (Revenue, USD Million, 2020–2034)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Non-specific Endonucleases Market Report Scope
|
Report Attributes |
Details |
|
Market Size in 2024 |
USD 353.60 Million |
|
Market Size in 2025 |
USD 374.98 Million |
|
Revenue Forecast by 2034 |
USD 641.80 Million |
|
CAGR |
6.15% from 2025 to 2034 |
|
Base Year |
2024 |
|
Historical Data |
2020–2023 |
|
Forecast Period |
2025–2034 |
|
Quantitative Units |
Revenue in USD Million and CAGR from 2025 to 2034 |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Industry Trends |
|
Segments Covered |
|
|
Regional Scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The global market size was valued at USD 353.60 million in 2024 and is projected to grow to USD 641.80 million by 2034.
The global market is projected to register a CAGR of 6.15% during the forecast period.
North America led the market in 2024 due to strong biotech infrastructure and advanced research capabilities.
A few of the key players in the market are ArcticZymes Technologies, New England Biolabs (NEB), Thermo Fisher Scientific Inc., GenScript Biotech, Promega Corporation, QIAGEN N.V., TransGen Biotech, RayBiotech, Inc., ACROBiosystems, Protean Ltd., c-LEcta GmbH, and Kerafast.
Recombinant non-specific endonucleases dominated in 2024 driven by high efficiency and broad research use.
The CDMOs/CMOs segment is projected to grow fastest due to rising outsourcing in biomanufacturing and R&D.
© 2025 Polaris Market Research and Consulting. All rights reserved
